Skip to main
LLY
LLY logo

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 40%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly reported a robust performance in the second quarter of 2025, exceeding expectations in both revenue and earnings, while also raising its full-year guidance, signaling strong operational momentum. Notably, the growth of Mounjaro sales outside the United States accelerated by 60% quarter-over-quarter, driven by successful market entries in Brazil, Mexico, and India. Additionally, the introduction of orforglipron presents a promising opportunity to expand the GLP-1 market with a convenient oral formulation, enhancing the company's product portfolio in the cardiometabolic sector.

Bears say

Eli Lilly faces significant downside risks that contribute to a negative outlook on its stock, particularly regarding pressure from pricing and rebates in an increasingly competitive market. The prescription trajectory for its drug tirzepatide is falling short of expectations, coupled with concerns over its failure to demonstrate cardiac outcome benefits in non-diabetic obese patients. Additionally, the company has reported a negative impact from Zepbound prescriptions, which is anticipated to hinder volumetric growth in the upcoming quarter.

Eli Lilly (LLY) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 40% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 15 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Nov 7, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $976.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $976.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.